Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
UNDERSTANDING YOUR OPTIONS Sleep Apnea & GLP-1 Coverage Important Clarification: Wegovy Is NOT FDA-Approved for Sleep Apnea On December 20, 2024, the FDA approved Zepbound (tirzepatide)not Wegovy as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity
In January 2026, the FDA approved oral semaglutide (Wegovy in pill form) for weight managementthe first GLP-1 receptor agonist available as a pill for weight loss
: : 500-1000 : : 500 : L- L-
Methods GLP-1 agonists included in the analysis were approved for treatment of obesity (Saxenda, Wegovy, Zepbound) and corresponding formulations that may potentially be used off-label for treatment of obesity (Mounjaro, Ozempic, Rybelsus, Victoza)
US$ 23.19
US$ 23.97
US$ 28.80
US$ 23.33
US$ 24.69
US$ 23.86
US$ 29.64
US$ 27.88
US$ 24.40
US$ 22.58
US$ 23.01
US$ 20.61
US$ 25.92
US$ 25.15
US$ 25.32
